ZAI LAB LIMITED Interest Expense
ZAI LAB LIMITED (ZLAB) reported Interest Expense of $2.25 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2025-02-27
- ZAI LAB LIMITED interest expense for the quarter ending 2024-03-31 was $113.00K.
- ZAI LAB LIMITED interest expense for the quarter ending 2023-03-31 was $0.00.
- ZAI LAB LIMITED interest expense for the quarter ending 2020-12-31 was $24.00K.
- ZAI LAB LIMITED interest expense for the quarter ending 2020-09-30 was $43.00K.
- ZAI LAB LIMITED interest expense for fiscal 2024 was $2.25M.
- ZAI LAB LIMITED interest expense for fiscal 2023 was $0.00.
- ZAI LAB LIMITED interest expense for fiscal 2022 was $0.00.
- ZAI LAB LIMITED interest expense for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month | Interest Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $2.25M 10-K · filed 2025-02-27 | ||||
| 2024-03-31 | $113.00K 10-Q · filed 2024-05-08 | ||||
| 2023-12-31 | $0.00 10-K · filed 2025-02-27 | ||||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-08 | ||||
| 2022-12-31 | $0.00 10-K · filed 2025-02-27 | ||||
| 2021-12-31 | $0.00 10-K · filed 2023-03-01 | ||||
| 2020-12-31 | $24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $67.00K derived: sum of 2 quarters · filed 2023-03-01 | $122.00K derived: sum of 3 quarters · filed 2023-03-01 | $181.00K 10-K · filed 2023-03-01 | |
| 2020-09-30 | $43.00K 10-Q · filed 2021-11-09 | $98.00K derived: sum of 2 quarters · filed 2021-11-09 | $157.00K 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $55.00K 10-Q · filed 2021-08-09 | $114.00K 10-Q · filed 2021-08-09 | |||
| 2020-03-31 | $59.00K 10-Q · filed 2021-05-10 | ||||
| 2019-12-31 | $293.00K 10-K · filed 2022-03-01 | ||||
| 2019-06-30 | $137.00K 6-K · filed 2020-09-11 | ||||
| 2018-12-31 | $40.00K 10-K · filed 2021-03-01 | $39.67K 20-F · filed 2019-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |